This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
ARSD / Arylsulfatase D · IHC design guide
Design Immunohistochemistry for ARSD
Plan ARSD staining in paraffin sections with the catalog antibody at 1:100–1:300 (datasheet). Compare granular cytoplasmic staining in bronchial respiratory epithelial cells with adipocytes, where staining was not detected (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
ARSD Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Granular cytoplasm (HPA tissue IHC); lysosome expected (UniProt) | |
| Staining pattern | Granular cytoplasm in glandular and respiratory epithelial cells (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen) | |
| Positive control | Adrenal gland+4 more · see all | |
| Negative control | Adipose tissue+2 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections. (standard IHC practice; not target-specific) | |
| Caveat | Staining and RNA show medium consistency (HPA tissue IHC) | |
| Regulation | Expression regulation not annotated (UniProt) | |
| Isoform / epitope | 3 isoforms; epitope coverage is unspecified (UniProt; datasheet) |
Section 1
Recommended ARSD IHC & IF Protocols
Compare the catalog antibody's IHC-P protocol with published ARSD staining in breast cancer and glioma specimens (PMC8560752; PMC10521731; PMC13547030).
| Sample | Paraffin-embedded human lung carcinoma tissue; fixative not specified (datasheet A08673-1) |
| Fixation | Image fixative and duration unreported (datasheet A08673-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in citrate buffer, pH 6.0, 20 min at 95–98 °C (standard rule: cytoplasmic / membrane antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit anti-ARSD, 1:100-1:300 (datasheet A08673-1) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | ARSD-positive staining in glandular cells of adrenal gland (HPA tissue IHC: High). HPA tissue profile: General cytoplasmic expression with a granular pattern. No signal in the no-primary control. |
💡Decision noteStart with citrate pH 6.0 retrieval at 95–98 °C for 20 min (page retrieval rule); the breast cancer study also used citrate pH 6.0 (PMC8560752).
Section 2
What Is the Expected ARSD Staining Pattern?
ARSD is lysosomal and has no annotated transmembrane segment (UniProt P51689). In paraffin IHC, expect granular cytoplasmic staining in positive cells, including glandular, respiratory epithelial, neuronal and glial cells (HPA tissue IHC). HPA rates its tissue staining Approved, with medium consistency between staining and RNA expression; interpret individual fields with that qualification (HPA tissue IHC).
| Granular cytoplasmic staining is strong in adrenal or appendix glandular cells. | This matches HPA's general cytoplasmic, granular profile and its High staining calls for these cells (HPA tissue IHC). Score the identified cells and their cytoplasm, rather than treating every stained structure in the section as ARSD positive (standard IHC practice). |
| The dominant signal is nuclear or outlines the cell surface, with little cytoplasmic granularity. | That distribution conflicts with the reported IHC pattern and lysosomal assignment (HPA tissue IHC; UniProt P51689). Check morphology and the antibody control before assigning specificity; compartment mismatch alone does not identify the artefact's cause (standard IHC practice). |
| Adipocytes, ovarian stroma cells or soft tissue fibroblasts stain as strongly as known-positive cells. | HPA reports ARSD as Not detected in those cell populations (HPA tissue IHC). Confirm cell identity and compare controls; unexpected staining can reflect cross-reactivity or endogenous detection activity, but the image alone cannot distinguish them (standard IHC practice). |
| Brown signal is diffuse across tissue, with no cell-defined granular pattern. | This is difficult to reconcile with HPA's granular cytoplasmic profile (HPA tissue IHC). Review the detection control, background distribution and counterstain before scoring it as ARSD; diffuse color alone is insufficient evidence of target localization (standard IHC practice). |
| A well-preserved adrenal or appendix glandular field has no detectable cytoplasmic signal. | HPA calls those glandular cells High, so an absent result warrants investigation (HPA tissue IHC). Check that the expected cells are present and assess the staining run with suitable controls; a single blank field does not establish biological absence (standard IHC practice). |
💡Expected ARSD appearanceCall a positive IHC result when identified HPA-positive cells show clear granular cytoplasmic staining, potentially High in adrenal or appendix glandular cells; isolated nuclear, surface or negative-cell staining is suspect (HPA tissue IHC; UniProt P51689).
| Compartment and topology | UniProt places ARSD in lysosomes and annotates no transmembrane segment (UniProt P51689). HPA describes granular cytoplasmic tissue staining (HPA tissue IHC). These records support a cytoplasmic pattern; they do not prove that each chromogenic granule is a lysosome. |
| Tissue and cell selection | HPA reports High staining in bronchial respiratory epithelial cells, caudate neurons, cerebellar granular-layer cells and cortical glia, as well as several glandular populations (HPA tissue IHC). Its RNA classification is low tissue specificity, so assess named cell populations rather than expecting a tissue-exclusive signal (HPA tissue IHC). |
| Antibody evidence | The tissue IHC profile is Approved, with medium consistency between antibody staining and RNA expression (HPA tissue IHC). HPA004694 is listed as IHC Approved; HPA063835 is listed as ICC Approved, with no IHC status supplied for it (HPA antibodies). These statuses do not validate another reagent. |
| Processing, glycosylation and isoforms | UniProt annotates signal residues 1–33, a 34–593 chain, glycosylation at 61, 128 and 347, and three isoforms (UniProt P51689). The supplied records give no antibody epitope or isoform-specific staining evidence, so do not attribute a weak field to cleavage, glycosylation or one isoform. |
| What should ICC-IF show? | HPA reports vesicles and lipid droplets as Approved ICC-IF locations, with images from A-549, MCF-7 and U2OS (HPA subcellular). Use that finding to interpret ICC-IF on its own guide page; the tissue IHC record establishes granular cytoplasm, without resolving those structures in paraffin sections (HPA tissue IHC). |
| Situation | Likely cause | Next action |
|---|---|---|
| No signal in an HPA High glandular population | The expected cells may be absent from the field, or the IHC run may have failed; HPA's High call alone cannot identify the cause (HPA tissue IHC; standard IHC practice). | Confirm glandular morphology, then compare a suitable positive control and the run's staining controls. Review the validated IHC conditions for the antibody used before calling the sample negative (standard IHC practice). |
| Mostly nuclear or continuous surface staining | The dominant distribution disagrees with ARSD's lysosomal assignment and HPA's granular cytoplasmic profile (UniProt P51689; HPA tissue IHC). | Recheck the compartment at higher magnification and compare antibody and detection controls. Record the mismatch rather than scoring that signal as expected ARSD (standard IHC practice). |
| Strong staining in a reported negative cell population | Adipocytes, ovarian stroma cells and soft tissue fibroblasts are Not detected in the supplied HPA tissue profile; misidentified cells or nonspecific detection are possibilities (HPA tissue IHC; standard IHC practice). | Identify the stained cells with morphology and compare nearby positive cells. Use an appropriate detection control to investigate endogenous activity before assigning cross-reactivity (standard IHC practice). |
| Uniform color or haze obscures granules | Diffuse background obscures the cell-defined granular pattern reported for ARSD, but does not establish a target-specific failure (HPA tissue IHC; standard IHC practice). | Inspect the detection control and background outside expected cells; review blocking, washes and chromogen development as general IHC variables (standard IHC practice). |
| Positive cells are weak while background is low | A weak result differs from HPA's High calls in selected cells, yet HPA rates tissue staining only medium-consistent with RNA expression (HPA tissue IHC). No ARSD-specific fixation or retrieval sensitivity is supplied. | Confirm the cell population and control performance. Review the antibody's validated IHC conditions and any retrieval used as general workflow checks; avoid claiming an ARSD-specific fixation effect (standard IHC practice). |
| A granular field contains both plausible positive and negative cells | HPA's calls differ by cell population, including High glandular or neural populations and Not detected adipocytes or fibroblasts (HPA tissue IHC). Mixed morphology can make a field-wide score misleading (standard IHC practice). | Score cytoplasmic granularity and intensity within identified cell types, using the HPA calls as comparators. Keep uncertain cells separate until morphology and controls support their identity (HPA tissue IHC; standard IHC practice). |
Experiment evidence
IHC & IF images showing ARSD staining
A08673-1 · IHCImmunohistochemistry analysis of paraffin-embedded human lung carcinoma tissue, using ARSD Antibody. The picture on the right is blocked wit
A08673-1 · IFImmunofluorescence analysis of MCF7 cells, using ARSD Antibody. The picture on the right is blocked with the synthesized peptide.
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000006756-ARSD/tissue/cerebral+cortex#imid_20281305
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000006756-ARSD/tissue/colon#imid_20289647
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000006756-ARSD/tissue/liver#imid_20289656
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000006756-ARSD/tissue/kidney#imid_20289649
HPA · ICC-IF A-549Human Protein Atlas immunofluorescence, A-549, antibody HPA063835; green = ARSD, blue = nucleus, red = microtubules.
HPA · ICC-IF A-549Human Protein Atlas immunofluorescence, A-549, antibody HPA063835; green = ARSD, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for ARSD IHC & IF
🧪Run breast first: its glandular cells should stain strongly (HPA: High in breast glandular cells). Use adipose tissue as the negative tissue (HPA: Not detected in adipocytes); adipocytes within the breast section, when present, should remain at background level as an internal negative reference (HPA: Not detected in adipocytes).
Positive control tissue: Adrenal gland (Glandular cells, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show ARSD in A-549, MCF-7, U2OS, with annotated localisation: Vesicles (approved), Lipid droplets (approved) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only control and an isotype control matched to the primary antibody’s host species and immunoglobulin class (standard IHC practice). Confirm specificity with a knockout sample or peptide block; peptide blocking is shown for the selected antibody in lung carcinoma tissue (A08673-1 caption). Quench endogenous peroxidase for chromogenic IHC, and assess autofluorescence separately for IF (standard IHC/IF practice).
⚠️Feasibility: A target-specific fixation window, retrieval dependency, and whether frozen sections or IF are easier are unreported in the supplied evidence; the selected paraffin-section caption also leaves the fixative unreported (A08673-1 caption). For IF interpretation, lipid-rich areas may complicate assessment of punctate signal because ARSD is reported at lipid droplets as well as vesicles (HPA subcellular).
HPA tissue IHC evidence for ARSD
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | Glandular cells | High | Protein (IHC) | HPA → |
| Appendix | Glandular cells | High | Protein (IHC) | HPA → |
| Breast | Glandular cells | High | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | High | Protein (IHC) | HPA → |
| Caudate | Neuronal cells | High | Protein (IHC) | HPA → |
Section 3
Advanced ARSD IHC Tips
Troubleshoot ARSD staining in paraffin sections by checking retrieval, cellular pattern, controls and scoring before interpreting chromogenic signal.
What should I change when ARSD staining is weak after retrieval?
Start with citrate pH 6.0 heat induced retrieval at 95–98 °C for 20 min on paraffin sections (page retrieval setting). Keep section thickness, heating vessel and cooling interval consistent across the comparison, since retrieval variation can change chromogenic intensity (standard IHC practice). If staining remains weak, compare a longer citrate exposure with a separately tested EDTA pH 9.0 condition as fallback options (standard IHC practice). Judge both against preserved morphology and the expected granular cytoplasmic pattern, rather than intensity alone (HPA: general cytoplasmic expression with a granular pattern). Record the chosen condition for every scoring batch (standard IHC practice).
Could fixation explain weak or uneven ARSD staining?
Target specific fixation sensitivity is unknown: the selected A08673-1 image identifies paraffin embedded lung carcinoma but reports no fixative (A08673-1 tissue IHC caption). For a controlled comparison, process matched specimens with a documented routine fixation condition, such as 10% neutral buffered formalin, and keep processing intervals consistent (standard IHC practice). Compare sections using the same citrate pH 6.0, 20 min retrieval and detection run (page retrieval setting; standard IHC practice). If signal tracks processing differences, repeat on matched material before changing the antibody concentration (standard IHC practice). Neither the tissue staining pattern nor protein topology establishes an ARSD specific fixation effect (HPA: tissue IHC profile; UniProt P51689 topology).
Which staining pattern fits ARSD in a tissue section?
Assess ARSD primarily as granular cytoplasmic staining: the tissue IHC profile reports that pattern, while UniProt assigns ARSD to lysosomes (HPA: tissue IHC profile; UniProt P51689 subcellular location). Approved cell imaging locations also include vesicles and lipid droplets, which can inform a punctate interpretation without establishing their identity in a chromogenic section (HPA: subcellular locations). Compare staining within defined cells, such as bronchial respiratory epithelium, where high staining is reported (HPA: High in bronchial respiratory epithelial cells). Diffuse nuclear color or broad extracellular deposits warrant review of morphology and controls before assignment to ARSD (UniProt P51689 subcellular location; standard IHC practice). Keep compartment calls separate from staining intensity scores (standard IHC practice).
Can this stain distinguish ARSD isoforms or processing states?
ARSD has 3 annotated isoforms, but the supplied antibody evidence does not map its epitope or establish isoform selectivity (UniProt P51689 isoforms; A08673-1 tissue IHC caption). The precursor loses signal peptide residues 1–33, leaving the annotated 34–593 chain (UniProt P51689 processing). Annotated glycosylation sites at 61, 128 and 347, plus a modified residue at 89, are relevant when checking an epitope map (UniProt P51689 modifications). Obtain the antibody epitope information before claiming recognition of every isoform or processed state (UniProt P51689 isoforms and processing; standard antibody validation practice). Score the observed cellular staining without assigning it to a particular isoform (standard IHC practice).
How should I check ARSD localisation by multiplex IF?
Use the separate IF/ICC workflow to compare ARSD with a lysosomal marker such as LAMP1 and a marker identifying the cell type being assessed (UniProt P51689: lysosome; standard IF practice). For bronchial respiratory epithelium, a cytokeratin marker can help define the cells that show high tissue staining (HPA: High in bronchial respiratory epithelial cells; standard IF practice). Choose a far red fluorophore for the weaker target and measure each channel against unstained tissue autofluorescence (standard IF practice). ARSD has no transmembrane segment, while its antibody epitope side is unspecified; verify epitope access before selecting permeabilisation (UniProt P51689 topology; A08673-1 tissue IHC caption). Test mild 0.1% detergent permeabilisation against an untreated control when intracellular access is needed (standard IF practice).
How can I separate ARSD signal from chromogenic background?
Run a no primary control through the same chromogenic detection steps to reveal secondary reagent and tissue background (standard IHC practice). For peroxidase and DAB detection, use a peroxide block, for example 3% hydrogen peroxide for 10 min, and check the result on the actual tissue (standard IHC practice). A protein block and antibody dilution series can reduce nonspecific staining while preserving granular cytoplasmic detail (HPA: tissue IHC profile; standard IHC practice). The A08673-1 paraffin image includes a synthesized peptide blocking comparison, which offers a product specific specificity check (A08673-1 tissue IHC caption). Interpret reduced staining with that control alongside tissue morphology and the no primary result (standard IHC practice).
What is a defensible way to score ARSD staining? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and region before scoring, since reported ARSD staining differs among cell types within tissues (HPA: tissue IHC profile). In that compartment, record the percentage of positive cells and intensity categories 0–3, then calculate an H-score on a 0–300 scale if needed (standard IHC practice). For a spatial question, report positive cell density per mm² of viable, evaluated tissue (standard IHC practice). Normalise comparisons to the same cell type or tissue area, section processing, retrieval and detection settings (standard IHC practice). Exclude necrosis and section edges using prespecified rules, and retain representative images for score review (standard IHC practice).
When should apparent ARSD positivity be treated as artefact?
Give greatest weight to intracellular granular cytoplasmic staining in identifiable cells, consistent with the tissue profile and lysosomal annotation (HPA: tissue IHC profile; UniProt P51689 subcellular location). Check whether the stained cell type fits the comparison: bronchial respiratory epithelial cells are reported High, whereas adipocytes are reported Not detected (HPA: bronchus and adipose tissue IHC). Nuclear dominant staining, edge concentrated color and necrotic deposits require morphology and control review before an ARSD call (UniProt P51689 subcellular location; standard IHC practice). Check a no primary section for endogenous peroxidase or detection background when using DAB (standard IHC practice). Peptide blocking in the A08673-1 lung carcinoma image supports that image's staining comparison without proving every new specimen specific (A08673-1 tissue IHC caption; standard IHC practice).
Boster reagents
Best ARSD / Arylsulfatase D IHC Antibodies
A08673-1 has IHC data from paraffin-embedded human lung carcinoma tissue and IF data from MCF7 cells; listed reactivity is human (IHC and IF image captions; catalog reactivity).
Real IHC data
Anti-Arylsulfatase D ARSD Antibody
Cat # A08673-1
A08673-1 shows IHC staining of paraffin-embedded human lung carcinoma tissue alongside a synthesized-peptide-blocked image (IHC image caption). The same SKU shows IF staining of MCF7 cells alongside a synthesized-peptide-blocked image (IF image caption).
Which to pick: Choose A08673-1 for paraffin-section tissue IHC based on its own IHC image; the fixative is unreported (IHC image caption). For cellular IF, A08673-1 lists IF and shows MCF7 cells; ICC is not separately listed (catalog applications; IF image caption). No cross-species option is documented: A08673-1 lists human reactivity, has a rabbit host, and has no specified clone (catalog reactivity; host; clone).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P51689 (ARSD_HUMAN, Arylsulfatase D).
- Human Protein Atlas. ARSD tissue IHC expression (reliability: Approved).
- Human Protein Atlas. ARSD subcellular location (ICC-IF): Localized to vesicles and lipid droplets..
- Human Protein Atlas. ARSD antibody validation summary (2 antibodies).
- ARSD, a novel ERα downstream target gene, inhibits proliferation and migration of breast cancer cells via activating Hippo/YAP pathway. Cell death & disease 2021 — PMC8560752.
- Arylsulfatase D is a prognostic biomarker that promotes glioma cells progression through JAK2/STAT3 pathway and M2 macrophage infiltration. Frontiers in oncology 2023 — PMC10521731.
- Arylsulfatase D promotes malignant phenotypes in glioblastoma cells and is linked to altered Hippo pathway phosphorylation. Frontiers in oncology 2026 — PMC13547030.
- PubMed PMID:7720070 — UniProt-cited evidence.
- PubMed PMID:11177574 — UniProt-cited evidence.
- PubMed PMID:15772651 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for ARSD (Arylsulfatase D). Expected localisation Granular cytoplasm (HPA tissue IHC); lysosome expected (UniProt). Antigen retrieval: Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen). Validated IHC antibody: A08673-1 at 1:100-1:300 (the product's own IHC validation image is shown). Controls (HPA): positive Adrenal gland (Glandular cells); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human lung carcinoma tissue; fixative not specified (datasheet A08673-1); 2. Fixation: Image fixative and duration unreported (datasheet A08673-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in citrate buffer, pH 6.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-ARSD, 1:100-1:300 (datasheet A08673-1); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Keep fixation consistent across sections. (standard IHC practice; not target-specific); Caveat: Staining and RNA show medium consistency (HPA tissue IHC); Isoform / epitope: 3 isoforms; epitope coverage is unspecified (UniProt; datasheet); Regulation: Expression regulation not annotated (UniProt). Evidence: UniProt P51689, HPA tissue IHC · Approved, HPA ICC-IF · vesicles and lipid droplets., Datasheet A08673-1, PMC8560752, PMC10521731. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/ARSD/immunohistochemistry-ihc-guide.